{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:17:43Z","timestamp":1783178263825,"version":"3.54.6"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08AI185260"],"award-info":[{"award-number":["K08AI185260"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaip.2026.02.029","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:39:58Z","timestamp":1778060398000},"page":"1023-1032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of In Vivo, In Vitro and Pharmacogenomic Diagnostic Approaches to Sulfonamide Allergy"],"prefix":"10.1016","volume":"14","author":[{"given":"Jamie L.","family":"Waldron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-2665","authenticated-orcid":false,"given":"Allison E.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.02.029_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2307\/3451714","article-title":"The sulfonamides","volume":"61","author":"Cohen","year":"1961","journal-title":"Am J Nurs"},{"key":"10.1016\/j.jaip.2026.02.029_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/all.12881","article-title":"Drug allergies documented in electronic health records of a large healthcare system","volume":"71","author":"Zhou","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.02.029_bib3","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib4","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2026.02.029_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12016-021-08872-3","article-title":"Sulfonamide hypersensitivity","volume":"62","author":"Chow","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib6","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jaip.2019.05.034","article-title":"Sulfonamide hypersensitivity: fact and fiction","volume":"7","author":"Khan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100856","article-title":"Antibiotic prophylaxis in immunosuppressed patients\u2014missed opportunities from trimethoprim-sulfamethoxazole allergy label","volume":"17","author":"Lee","year":"2024","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2026.02.029_bib8","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2026.02.029_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/infdis\/168.2.314","article-title":"Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count","volume":"168","author":"Kennedy","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaip.2026.02.029_bib10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(83)90627-X","article-title":"Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men","volume":"2","author":"Jaffe","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.02.029_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/imj.70057","article-title":"Impact of sulfonamide allergy label on clinical outcomes of acute cystitis: a retrospective matched cohort study","volume":"55","author":"Moussa","year":"2025","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaip.2026.02.029_bib12","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199212243272604","article-title":"A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021","volume":"327","author":"Hardy","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.02.029_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14355","article-title":"Sulfonamide allergy label and the risk of opportunistic infections in solid organ transplant recipients\u2014a retrospective matched cohort study","volume":"26","author":"Al-Shaikhly","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jaip.2026.02.029_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1592\/phco.26.4.551","article-title":"Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients","volume":"26","author":"Hemstreet","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaip.2026.02.029_bib15","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.jaip.2024.06.036","article-title":"Anaphylaxis in practice: a guide to the 2023 Practice Parameter Update","volume":"12","author":"Wang","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/1574886311308020004","article-title":"A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting","volume":"8","author":"Nguyen","year":"2013","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jaip.2026.02.029_bib17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00130832-200410000-00013","article-title":"The immunological and clinical spectrum of delayed drug-induced exanthems","volume":"4","author":"Lerch","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1365-4362.1998.00451.x","article-title":"Drugs causing fixed eruptions: a study of 450 cases","volume":"37","author":"Mahboob","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaip.2026.02.029_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-4632.2011.05107.x","article-title":"Baboon syndrome\/SDRIFE due to sulfamethoxazole-trimethoprim","volume":"52","author":"Culav","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clindermatol.2015.04.008","article-title":"Baboon syndrome and toxic erythema of chemotherapy: fold (intertriginous) dermatoses","volume":"33","author":"Wolf","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaip.2025.02.027","article-title":"Serum sickness-like reactions clinical characteristics and management: a systematic review","volume":"13","author":"Khalaf","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib24","author":"Milan Mukherjee"},{"key":"10.1016\/j.jaip.2026.02.029_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jdv.18808","article-title":"Management and treatment outcome of DRESS patients in Europe: an international multicentre retrospective study of 141 cases","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2026.02.029_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","article-title":"Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US","volume":"158","author":"Creadore","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2026.02.029_bib29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.anai.2014.08.006","article-title":"Trimethoprim-sulfamethoxazole-induced aseptic meningitis\u2014not just another sulfa allergy","volume":"113","author":"Bruner","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.anai.2021.01.034","article-title":"Trimethoprim anaphylaxis confirmed by a novel basophil activation test","volume":"126","author":"Pumar","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0091-6749(96)70295-6","article-title":"Anaphylaxis to trimethoprim","volume":"97","author":"Caba\u00f1as","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0091-6749(94)90120-1","article-title":"Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins","volume":"94","author":"Meekins","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib33","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0161-5890(88)90050-8","article-title":"Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole","volume":"25","author":"Harle","year":"1988","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/0091-6749(91)90186-R","article-title":"Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine","volume":"88","author":"Gruchalla","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib35","article-title":"Sulfonamide allergies","volume":"7","author":"Giles","year":"2019","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.jaip.2026.02.029_bib36","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2009.10.031","article-title":"Stimulation of human T cells with sulfonamides and sulfonamide metabolites","volume":"125","author":"Castrejon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjp.0702453","article-title":"Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity","volume":"126","author":"Naisbitt","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaip.2026.02.029_bib39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0090-9556(25)08967-6","article-title":"Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity","volume":"19","author":"Cribb","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jaip.2026.02.029_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2026.02.029_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/clpt.1991.3","article-title":"Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions","volume":"49","author":"Rieder","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2026.02.029_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101087","article-title":"Drug hypersensitivity reactions in children in clinical practice: a WAO Statement","volume":"18","author":"Berges-Gimeno","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2026.02.029_bib43","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1592\/phco.24.9.856.36106","article-title":"Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group","volume":"24","author":"Brackett","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaip.2026.02.029_bib44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000312632","article-title":"Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole","volume":"153","author":"Zawodniak","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib45","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa022963","article-title":"Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics","volume":"349","author":"Strom","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.02.029_bib46","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.jaip.2021.07.027","article-title":"Reply to \u201cThe safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy\u201d","volume":"9","author":"Krantz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib47","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamainternmed.2020.0403","article-title":"Development and validation of a penicillin allergy clinical decision rule","volume":"180","author":"Trubiano","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaip.2026.02.029_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16776","article-title":"Development and validation of a sulfa antibiotic allergy clinical decision rule","volume":"6","author":"Waldron","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaip.2026.02.029_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19113","article-title":"International validation of the SULF-FAST risk-stratification tool for sulfonamide antibiotic allergy","volume":"8","author":"Stehlin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaip.2026.02.029_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.388","article-title":"RNA expression profiling in sulfamethoxazole-treated patients with a range of in vitro lymphocyte cytotoxicity phenotypes","volume":"6","author":"Reinhart","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jaip.2026.02.029_bib51","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1016\/j.jaip.2025.05.056","article-title":"Utility of IFN-\u03b3 enzyme-linked immunospot as adjunctive diagnostic for severe T cell-mediated reactions to cotrimoxazole in high HIV and tuberculosis settings","volume":"13","author":"Selim","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0091-6749(03)01783-4","article-title":"Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics","volume":"112","author":"Empedrad","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/cod.14692","article-title":"Patch testing in non-immediate hypersensitivity to cotrimoxazole: is it useful?","volume":"91","author":"Soares","year":"2024","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2026.02.029_bib54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/cod.14090","article-title":"Patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): a literature review","volume":"86","author":"de Groot","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2026.02.029_bib55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0536.1999.tb06127.x","article-title":"Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption","volume":"41","author":"Ozkaya-Bayazit","year":"1999","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2026.02.029_bib56","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2023.10.021","article-title":"In situ patch test and repeated open application test for fixed drug eruption: a multicenter study","volume":"12","author":"Traineau","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaip.2019.07.003","article-title":"Oral challenge with trimethoprim-sulfamethoxazole in patients with \u201csulfa\u201d antibiotic allergy","volume":"8","author":"Krantz","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib58","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1016\/j.jaip.2021.05.046","article-title":"The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy","volume":"9","author":"Rose","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib59","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaip.2021.11.024","article-title":"A single- or two-step challenge versus a six-step challenge in non-HIV-infected patients with a sulfonamide antibiotic allergy label: a retrospective case series","volume":"10","author":"Motoa","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.anai.2025.09.008","article-title":"Risk factors and challenge outcomes in trimethoprim-sulfamethoxazole hypersensitivity in HIV-negative patients: a multicenter retrospective report","volume":"136","author":"Kinate","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaip.2013.11.002","article-title":"Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction","volume":"2","author":"Pyle","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.18176\/jiaci.0708","article-title":"Management of hypersensitivity to trimethoprim-sulfamethoxazole with an ultrarapid desensitization protocol in HIV infection","volume":"32","author":"Villarreal-Gonz\u00e1lez","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib63","first-page":"309","article-title":"Desensitization to co-trimoxazole in a patient with fixed drug eruption","volume":"18","author":"Patriarca","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2022.100480","article-title":"Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions","volume":"47","author":"Nakkam","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jaip.2026.02.029_bib65","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cpt.1915","article-title":"Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I Genotypes and haplotypes","volume":"108","author":"Sukasem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2026.02.029_bib66","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2019.12.025","article-title":"Association of HLA-A\u221711:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients","volume":"140","author":"Nakamura","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaip.2026.02.029_bib67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5455\/msm.2025.37.111-116","article-title":"Association between HLA-A\u221702:07 and fixed drug eruption caused by sulfamethoxazole-trimethoprim","volume":"37","author":"Thi","year":"2025","journal-title":"Mater Sociomed"},{"key":"10.1016\/j.jaip.2026.02.029_bib68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2026.02.029_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1755-8794-5-32","article-title":"Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV\/AIDS patients","volume":"5","author":"Wang","year":"2012","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaip.2026.02.029_bib70","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jaip.2025.08.001","article-title":"HLA-B alleles with shared peptide binding specificities define global risk of co-trimoxazole-induced severe cutaneous adverse drug reactions","volume":"13","author":"Li","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.02.029_bib71","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.02.029_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2026.02.029_bib73","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.2003.01754.x","article-title":"Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity","volume":"55","author":"Alfirevic","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2026.02.029_bib74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/FPC.0b013e328357a735","article-title":"Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity","volume":"22","author":"Sacco","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2026.02.029_bib75","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/pgs.14.69","article-title":"HLA-B\u221713:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population","volume":"15","author":"Yang","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2026.02.029_bib76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/tpj.2015.25","article-title":"HLA-B\u221759:01: a marker for Stevens-Johnson syndrome\/toxic epidermal necrolysis caused by methazolamide in Han Chinese","volume":"16","author":"Yang","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2026.02.029_bib77","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.10.54","article-title":"HLA-B\u22175901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Kim","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2026.02.029_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1417","article-title":"PharmGKB: a worldwide resource for pharmacogenomic information","volume":"10","author":"Barbarino","year":"2018","journal-title":"Wiley Interdiscip Rev Syst Biol Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:46:36Z","timestamp":1783176396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2213219826001819"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.02.029","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of In Vivo, In Vitro and Pharmacogenomic Diagnostic Approaches to Sulfonamide Allergy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}